Albireo Pharma — Biodel — Investor Presentation (October 2014)
42 slides from Albireo Pharma's investor presentation, Oct 27, 2014
Slide 1: Biodel Corporate Presentation October 2014
Biodel Corporate Presentation October 2014
Slide 2: Forward Looking Statements
Corporate Presentation September 2013 1 Forward Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements include statements about future activities related to the clinical
Slide 3: Company Overview
Corporate Presentation September 2013 2 ■ Focused on large and growing diabetes markets ■ Premium priced product opportunities with long patent life ■ Innovation through formulation and device technology development ■ Optimize PK, PD and stability of approved therapeutics ■ Rapid development through
Slide 4: Biodel Pipeline: A Diversified and De-Risked Portfolio
Corporate Presentation September 2013 3 Biodel Pipeline: A Diversified and De - Risked Portfolio Research Preclinical Phase 1 Phase 2 Ph 3/ Pivotal NDA Target Glucagon Program GEM for Rescue N/A POC 4Q14 2H15 4Q15/1H16 UniJect TM for Rescue Artificial Pancreas - SBIR Ultra - Rapid - Acting Prandial
Slide 5: Portfolio Strategy To Maximize Shareholder Value
Corporate Presentation September 2013 4 Portfolio Strategy To Maximize Shareholder Value $$$ Develop to Proof of Concept to Maximize Partnering Value Likely Greater ROI if Biodel Commercializes in Defined Markets $ $$$ Commercialization Investment Glucagon UniJect TM Prandial URAI (BIOD - 123, analo
Slide 6: Portfolio Strategy To Maximize Shareholder Value
Corporate Presentation September 2013 5 Portfolio Strategy To Maximize Shareholder Value $$$ Develop to Proof of Concept to Maximize Partnering Value $ $$$ Commercialization Investment Glucagon UniJect TM Prandial URAI (BIOD - 123, analogs) BIOD - 531 (Mix Segment) BIOD - 531 (Insulin Resistant Segm
Slide 7: Glucagon for Severe Hypoglycemia
Corporate Presentation September 2013 6 Glucagon for Severe Hypoglycemia ■ Marketed glucagon is unstable as a liquid and must be stored as a lyophilized cake requiring seven or more steps for administration ■ Requisite care giver training and “fear factor” are the largest barriers ■ Needlestick prot
Slide 8: Current Glucagon Limitations
Corporate Presentation September 2013 7 Current Glucagon Limitations ■ Seven or more steps required for reconstitution and administration ■ Difficult care giver training required ■ Risk of dosing error ■ Needle exposure ■ Complexity results in underuse of glucagon as a rescue treatment ■ Only 10% to
Slide 9: Glucagon Emergency Rescue: Two Planned Devices
Corporate Presentation September 2013 8 Glucagon Emergency Rescue: Two Planned Devices Auto Reconstitution GEM (Adult and Pediatric with needle stick protection) Ultra Portable UniJect TM (Adult and Pediatric)
Slide 10: Glucagon Emergency Rescue: Two Planned Devices
Corporate Presentation September 2013 9 Glucagon Emergency Rescue: Two Planned Devices Auto Reconstitution Glucagon Emergency Management (GEM) (Adult and Pediatric with needle stick protection) ▪ Institutional usage ▪ Ambulance ▪ Long Term Care ▪ Hospitals ▪ Comparable in size to EpiPen ® ▪ Easy to
Slide 11: Biodel's Room Temperature Intuitive Portable GEM
Corporate Presentation September 2013 10 Biodel’s Room Temperature Intuitive Portable GEM Requires Little to No Training Rescue device in carrying case Twist to remove case (reconstituted glucagon ready for injection) Needle shield removed, dose injected 1 2 3 After dose delivery, the needle is auto
Slide 12: PK and PD Profiles in Dogs of BIOD-961 vs. Lilly and Novo
Corporate Presentation September 2013 11 Pharmacokinetic and Pharmacodynamic Profiles in Dogs of BIOD - 961* Vs. Lilly and Novo Glucagon Rescue Products 50 70 90 110 130 150 170 190 210 -50 0 50 100 150 Glucose mg/dL Time (min) Pharmacodynamics: Mean Glucose ( n=8) BIOD-961 Lilly Novo 0 5000 10000 1
Slide 13: Ultra Portable UniJect Concept
Corporate Presentation September 2013 12 Protective Case With Clip (size of business card) Interviewed CDEs and patients prefer the UniJect TM over a standard auto - injector Ultra Portable UniJect TM Concept
Slide 14: Glucagon Market – Sources of Potential Growth
Corporate Presentation September 2013 13 0 50 100 150 200 250 300 350 Current Long Trem Care Emergency Responder Type 2 Type 1 Pricing Premium New Market $MM Glucagon Market – Sources of Potential Growth Pricing Premium Type 1 Type 2 Emergency Responder Long Term Care Type 1 Type 2 Emergency Respond
Slide 15: GEM for Severe Hypoglycemia
Corporate Presentation September 2013 14 GEM for Severe Hypoglycemia ■ Room temperature presentation ■ Small, portable user - friendly device ■ Requires little to no training Biodel Solution Calendar Q 1H13 2H13 1Q14 2Q14 3Q14 4Q14 2015 Milestones Engage Fill/Finish Manufacturer Acquire Proprietary
Slide 16: Portfolio Strategy To Maximize Shareholder Value
Corporate Presentation September 2013 15 Portfolio Strategy To Maximize Shareholder Value $$$ Develop to Proof of Concept to Maximize Partnering Value Likely Greater ROI if Biodel Commercializes in Defined Markets $ $$$ Commercialization Investment Glucagon UniJect TM Prandial URAI (BIOD - 123, anal
Slide 17: Marketed Prandial and Prandial/Basal Insulin Combo Products
Corporate Presentation September 2013 16 Marketed Prandial and Prandial/Basal Insulin Combo Products * Preparations of human insulin or rapid – acting analog prandial insulins such as Humalog and NovoLog premixed with intermediate - acting neutral protamine insulins in a variety of ratios such a
Slide 18: Ultra-Rapid-Acting Insulins May Represent a Step Change in Insulin Therapy
Corporate Presentation September 2013 17 Ultra - Rapid - Acting Insulins Which Replicate “Normal” Insulin Response May Represent a Step Change in Insulin Therapy Ultra - Rapid - Acting Insulins May Address the Market’s Unmet Need 2014 ■ Novo Nordisk: “NN1218” Phase 3 initiated in late 2013 ■ Halozym
Slide 19: Patented Unique Mechanism Results in More Rapid Absorption
Corporate Presentation September 2013 18 Patented Unique Mechanism Results in More Rapid Absorption Relative to Marketed Prandial Insulins Destabilize Hexamer (EDTA/Citrate) Increase Monomers/ Dimers More Rapid Absorption United States ■ Patent: US7279457 ■ Expiration: 2026 European Union ■ Patent:
Slide 20: Biodel Insulin Pipeline: Comparison to Major Insulin Players
Corporate Presentation September 2013 19 Biodel Pipeline of Ultra - Rapid - Acting Prandial and Prandial/Basal Combo Insulin Products: Comparison to Major Insulin Players * Preparations of human insulin or rapid – acting analog prandial insulins such as Humalog and NovoLog premixed with intermed
Slide 21: Biodel's Ultra-Rapid-Acting Insulin Portfolio
Corporate Presentation September 2013 20 Biodel’s Ultra - Rapid - Acting Insulin Portfolio BIOD - 531 (U400 RHI based with MgSO 4 ) ▪ Phase 1: Superior PK/PD compared to both Humulin ® R U - 500 Humalog ® 75/25 mix ▪ Excellent injection site tolerability BIOD - 123 (RHI based with MgSO 4 ) ▪ Phase 1
Slide 22: Biodel's Ultra-Rapid-Acting Insulin Portfolio
Corporate Presentation September 2013 21 Biodel’s Ultra - Rapid - Acting Insulin Portfolio BIOD - 531 (U400 RHI based with MgSO 4 ) ▪ Phase 1: Superior PK/PD compared to both Humulin ® R U - 500 Humalog ® 75/25 mix ▪ Excellent injection site tolerability BIOD - 123 (RHI based with MgSO 4 ) ▪ Phase 1
Slide 23: BIOD-531 Targets Two Segments of the Type 2 Diabetes Market
Corporate Presentation September 2013 22 BIOD - 531, Concentrated Ultra - Rapid - Acting Prandial/Basal Insulin, Targets Two Segments of the Type 2 Diabetes Market Humulin R U - 500 (Concentrated RHI - based Insulin) ▪ For severely insulin resistant type 2 patients requiring >200 IU daily ▪ Reduce
Slide 24: BIOD-531 vs. Humulin R U-500 PK/PD Data
Corporate Presentation September 2013 23 -20 10 40 70 100 130 160 0 250 500 750 1000 1250 Insulin Concentration (Change from Baseline) ( μ U/ mL ) Time (min) BIOD - 531 U - 500 R Pharmacokinetic Profile Ultra - Rapid - Acting Absorption Profile of BIOD - 531 Vs. Humulin ® R U - 500 (1.0 U/kg): Pharm
Slide 25: BIOD-531 vs. Humalog Mix 75/25 PK/PD Data
Corporate Presentation September 2013 24 -20 10 40 70 0 250 500 750 1000 1250 Insulin/ Lispro Concentration (Change from Baseline) ( μ U/ mL ) Time (min) Pharmacokinetic Profile BIOD - 531 Humalog ® Mix 75/25 Ultra - Rapid - Acting Absorption Profile of BIOD - 531 Vs. Humalog ® Mix 75/25 (0.5 U/kg):
Slide 26: Completed Phase 2 Meal Study - Trial Design
Corporate Presentation September 2013 25 Completed Phase 2 Meal Study 3 - 152 Trial Design BIOD - 531 (Pre - M) 75/25 (Pre - M) BIOD - 531 (Post - M) U - 500 (Pre - M) 75/25 (Pre - M) BIOD - 531 (Post - M) 75/25 (Pre - M) BIOD - 531 (Post - M) 75/25 (Pre - M) BIOD - 531 (Post - M) Visit 1 - 2 ( scre
Slide 27: Study 3-152: Mean Glucose Responses
Corporate Presentation September 2013 26 75 100 125 150 175 200 225 250 275 300 -60 0 60 120 180 240 300 360 420 480 540 600 660 720 Blood Glucose (mg/dl) Minutes Study 3 - 152: Mean Glucose Responses to BIOD - 531 Vs. Humalog Mix 75/25 and Humulin R U - 500 Test insulin (Before or After Standar
Slide 28: Average Glucose Concentrations: BIOD-531 vs. Comparators
Corporate Presentation September 2013 27 150 175 200 225 250 275 After Breakfast After Lunch Overall Test Period Average Glucose Concentration (mg/dl) BIOD-531Pre-Meal Humalog® Mix 75/25 Pre-Meal Humulin® R U-500 Pre-Meal BIOD-531 Post-Meal * # * # * * # * # Average Glucose Concentrations: BIOD - 53
Slide 29: Percentage of Glucose Values in Target Range
Corporate Presentation September 2013 28 Percentage of Glucose Values Between 70 - 180 mg/dl Target Range: BIOD - 531 Vs. Humalog ® Mix 75/25 Vs. Humulin ® R U - 500 * # * # * # * #
Slide 30: Ongoing Phase 2 Meal Study - Trial Design
Corporate Presentation September 2013 29 Ongoing Phase 2 Meal Study 3 - 151 Trial Design BIOD - 531 (Pre - M) 75/25 (Pre - M) BIOD - 531 (Post - M) U - 500 (Pre - M) 75/25 (Pre - M) BIOD - 531 (Post - M) 75/25 (Pre - M) BIOD - 531 (Post - M) 75/25 (Pre - M) BIOD - 531 (Post - M) Visit 1 - 2 ( screen
Slide 31: BIOD-531: Ultra-Rapid-Acting Prandial with Basal Profile and Reduced Volume
Corporate Presentation September 2013 30 BIOD - 531: Ultra - Rapid - Acting Prandial with Suitable Duration of Action/Basal Profile and Reduced Volume of Injection Insulin Product Desired Attribute for Treatment of Type 2 Diabetes Patients Prandial Coverage Basal Coverage Reduced Volume of Injection
Slide 32: BIOD-531 Late Stage Clinical Development Plans
Corporate Presentation September 2013 31 BIOD - 531 Late Stage Clinical Development Plans: Phase 3 Designed With Recent Written FDA Feedback ■ Phase 2b: □ Study 3 - 250 : Randomized, parallel group study in patients with Type 2 DM, BIOD - 531 vs. Humalog ® Mix 75/25, 6 month (3 - months titration, 3
Slide 33: BIOD-531 Development Plans
Corporate Presentation September 2013 32 BIOD - 531Concentrated Ultra - Rapid - Acting Prandial /Basal Insulin Development Plans Calendar Q 4Q13 1Q14 2Q14 3Q14 4Q14 1H15 2H15 2016 Milestones Initiated Phase 1 Top Line Phase 1 Data Initiated two Phase 2a Meal Studies 3 - 151 & 3 - 152 FDA Feedback &
Slide 34: Biodel's Ultra-Rapid-Acting Insulin Portfolio
Corporate Presentation September 2013 33 Biodel’s Ultra - Rapid - Acting Insulin Portfolio BIOD - 531 (U400 RHI based with MgSO 4 ) ▪ Phase 1: Superior PK/PD compared to both Humulin ® R U - 500 Humalog ® 75/25 mix ▪ Excellent injection site tolerability BIOD - 123 (RHI based with MgSO 4 ) ▪ Phase 1
Slide 35: BIOD-123 Phase 2: Achieved Primary Endpoint
Corporate Presentation September 2013 34 BIOD - 123 Phase 2: Achieved Primary Endpoint and Showed Statistically Significant Lower Glucose Excursions -0.4 -0.3 -0.2 -0.1 0 0.1 0 6 12 18 HbA1c (%) Change from Baseline Week BIOD-123 (n=65) Lispro (n=66) Mean “ SE HbA1c: Primary Non - inferiority Analys
Slide 36: BIOD-123 Data Comparable to Novo Nordisk's FIAsp
Corporate Presentation September 2013 35 BIOD - 123 Data is Comparable to Novo Nordisk’s FIAsp (faster - acting insulin aspart) in Meal Study
Slide 37: Biodel's Ultra-Rapid-Acting Insulin Portfolio
Corporate Presentation September 2013 36 Biodel’s Ultra - Rapid - Acting Insulin Portfolio BIOD - 531 (U400 RHI based with MgSO 4 ) ▪ Phase 1: Superior PK/PD compared to both Humulin ® R U - 500 Humalog ® 75/25 mix ▪ Excellent injection site tolerability BIOD - 123 (RHI based with MgSO 4 ) ▪ Phase 1
Slide 38: Lispro-Based BIOD-250 Pharmacokinetic Profile
Corporate Presentation September 2013 37 0 20 40 60 80 0 60 120 180 240 300 360 420 480 Insulin Concentration ( μ U/mL) Time (min) BIOD-250 Humalog® Pharmacokinetic Profile 0 20 40 60 80 0 10 20 30 40 50 60 Insulin Concentration ( μ U/ mL ) Time (min) Early Absorption Pharmacokinetic Profile In Man,
Slide 39: Next Steps for BIOD-123 & Analog-Based Insulin Program
Corporate Presentation September 2013 38 Next Steps for BIOD - 123 & Analog - Based Ultra - Rapid - Acting Prandial Insulin Program Calendar Q 1H13 2H13 1Q14 2Q14 3Q14 4Q14 2015 RHI Ultra - Rapid - Acting Insulin Positive Top Line Data Phase 2 Received FDA Feedback on Pivotal Trial, Tox, CV Requirem
Slide 40: News Flow & Projections
Corporate Presentation September 2013 39 News Flow & Projections Calendar Q 1Q14 2Q14 3Q14 4Q14 2015 RHI Ultra - Rapid - Acting Insulin End of Phase 2 FDA Feedback Analog Ultra - Rapid - Acting Insulin Glucagon Submit IND Submit NDA Initiate Clinical Trial Concentrated Ultra - Rapid - Acting Insulin
Slide 41: The Opportunity: Multiple Programs with Near Term Upside
Corporate Presentation September 2013 40 The Opportunity: Multiple Programs with Near Term Upside ■ Focused on large and growing diabetes market ■ Diversified and derisked portfolio ■ Proprietary formulation and device technologies ■ Modest investment to 2015 NDA utilizing rapid 505(b)(2) regulatory
Slide 42: Biodel
Biodel Corporate Presentation October 2014